RxDoctor Payments Data

Troy Larson, MD

Urology · Columbia, TNNPI 1023542610

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (28.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 32.8% of the total. Reporting peaked in 2023 at $15,312 and has fallen 94.0% since, to $913 in 2025.

$18,249in general payments, 2019–2025

Across 110 payments — averaging $165.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Uromedica, Incorporated$6K
  • Boston Scientific$5K
  • Calyxo, Inc.$189
  • Stryker$144
  • Ambu Inc.$138
  • plus $851 from 18 others

What the payments were for

  • Consulting fees$5,00027%
  • Travel & lodging$5,18628%
  • Food & beverage$3,56320%
  • Education$4,50025%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,249 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$213,562
Medicare patients
423
Services billed
7,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Solifenacin Succinate118$11,060
MyrbetriqMirabegron13$7,657
Tamsulosin Hcl486$6,974
Finasteride318$4,590
Testosterone17$3,027
Testosterone Cypionate91$2,806
Potassium Citrate ErPotassium Citrate24$2,682
Silodosin13$1,026
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst66$909
Alfuzosin Hcl ErAlfuzosin Hcl34$795
Oxybutynin Chloride ErOxybutynin Chloride21$730
Ketorolac Tromethamine28$426
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim86$389
Cyclobenzaprine Hcl94$362
Dutasteride21$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$19$7,65713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →